A randomized controlled trial found that vaginal estrogen delivered superior relief of vaginal dryness and dyspareunia compared to non-hormonal vaginal moisturizer in breast cancer survivors on aromatase inhibitors, with evidence of minimal systemic estrogen absorption in most participants.
The VEMORA trial, published in Breast Cancer Research and Treatment, is a randomized controlled trial directly comparing intravaginal estrogen therapy to a non-hormonal vaginal moisturizer in breast cancer survivors receiving aromatase inhibitor (AI) therapy. Results demonstrated that vaginal estrogen produced meaningfully greater improvements in both vaginal dryness and dyspareunia—hallmark symptoms of genitourinary syndrome of menopause (GSM)—than the non-hormonal comparator.
Aromatase inhibitors, used as adjuvant endocrine therapy in hormone receptor-positive breast cancer, profoundly suppress systemic and local estrogen levels, frequently causing or exacerbating GSM. This creates a clinical dilemma, as oncologists have historically been cautious about prescribing any estrogen-containing product in this population due to theoretical concerns about recurrence risk. The VEMORA findings offer prospective evidence that low-dose vaginal estrogen is associated with minimal systemic absorption in the majority of participants, providing a mechanistic rationale for its use.
Despite these encouraging results, the investigators acknowledged that the trial was not powered or designed to assess long-term oncologic safety endpoints. Larger studies with extended follow-up durations will be necessary to characterize recurrence risk and sustained efficacy before definitive clinical guidance can be established for this population.
Key points
- VEMORA is a randomized controlled trial comparing vaginal estrogen to non-hormonal moisturizer in breast cancer survivors on aromatase inhibitors.
- Vaginal estrogen produced significantly greater improvement in vaginal dryness and dyspareunia than non-hormonal therapy.
- Systemic estrogen exposure was minimal in most participants receiving intravaginal estrogen, supporting a favorable local-to-systemic absorption profile.
- The trial does not establish long-term oncologic safety; larger, longer-duration studies are required.
- Findings provide the first prospective comparative evidence to inform GSM management in AI-treated breast cancer survivors.
Why it matters
Genitourinary syndrome of menopause is highly prevalent and undertreated in breast cancer survivors on aromatase inhibitors, where non-hormonal options often provide inadequate symptom relief. VEMORA offers prospective data to support individualized discussions about low-dose vaginal estrogen use in this population, while underscoring the need for long-term safety data.